

Health

Pharma & Biotech

Written by:

Jonathan Jackson



Proactive has a commercial relationship with Actinogen Medical Ltd. This article was produced independently under Proactive's [Editorial Standards Policy](#).

[Disclaimer](#)
[No investment advice](#)

[About this content](#)

[Editorial Standards & Policies](#)

Share article



Actinogen Medical Ltd (ASX:ACW, OTC:ATGGF) ...

Actinogen Medical targets key FY27 catalysts

Last updated: 10:20 28 Aug 2026 AEST, First published: 09:20 28 Aug 2026 AEST



Actinogen Medical targets key
Proactive Investors



0:03 / 3:57



More videos

Actinogen Medical CFO Will Souter talked with Proactive about the company's FY2026 milestones, its upcoming XanaMIA Alzheimer's disease trial results in November, and the priorities that could shape its progress through FY2027.

Souter said the past year had been significant for Actinogen Medical, with the current Alzheimer's disease study nearing completion after several years of work. "It's been a big journey and the guys have done an amazing job to bring it all the way to the conclusion that's just around the corner with results in November.

Alongside progress with XanaMIA, Souter highlighted regulatory alignment with both the US Food and Drug Administration and the European Medicines Agency. He said this had provided the company with clear guidance on the steps required following the November results. Actinogen Medical also published a journal article during the year highlighting activity of its molecule in patients with depression.

Souter also discussed the company's financial position and spending priorities. He said most expenditure had been directed toward eligible research and development activities, resulting in an anticipated R&D rebate of nearly \$11 million. Combined with a pro forma cash balance of just under \$17 million at June 30, he said the company was positioned to respond to the November trial results and move into planned activities during 2027, with funding extending to mid-2027 and beyond.

A stronger balance sheet could also support potential partnership discussions following the trial readout. Souter said Actinogen Medical's three key objectives were to

Most read

Tech

Tech Bytes: Nvidia adds US\$441 billion in a...

2 days, 4 hours ago

Health

Percheron Therapeutics partners with...

2 days, 14 hours ago

Mining

Alien Metals shares rise 4% after...

2 days, 20 hours ago

Mining

Resolution Minerals extends gold...

2 days, 3 hours ago

Sign up to receive alerts and news direct to your inbox

Sign up for Newsletter



successfully complete XanaMIA and deliver a high-quality final data set in November, continue regulatory and clinical planning for a final pivotal trial in 2027, and prepare for potential discussions with global partners if the results are successful.

Notifications Powered by iZooto

Visit Proactive's YouTube channel for more interviews and market updates. If you found this video useful, give it a like, subscribe to the channel and enable notifications for future content.

Watch >



05.17




Actinogen Medical targets November XanaMIA results highlighting strong June...

Actinogen Medical Ltd managing director and CEO Dr Steven Gourlay talked with Proactive about the company's June quarter progress, including preparations for the pivotal XanaMIA Alzheimer's disease trial topline results expected in November 2026. Gourlay said the fully enrolled Phase 2b/3 trial...

on 30/7/26





proactive


05.20



Health

Actinogen targets \$20B Alzheimer's market with Xanamem

on 26/3/25



proactive

04.57




Health

Actinogen Medical with Proactive at ASX Small and Mid Cap Conference

on 27/3/24





proactive


10.58



Health

Actinogen Medical delivers strong half-year results as it develops...

on 28/2/24



proactive

08.19



Health

Actinogen moves to next stage of Alzheimer's treatment trials

on 1/11/18

